Artículo de revista
Redefining cut-points for high symptom burden of the global initiative for chronic obstructive lung disease classification in 18,577 patients with chronic obstructive pulmonary disease
Fecha
2017Registro en:
JAMDA 18 (2017) 1097.e11e1097.e24
Autor
Smid, Dionne E.
Franssen, Frits M.E.
Gonik, Maria
Mendoza Inzunza, Laura
Institución
Resumen
Background: Patients with chronic obstructive pulmonary disease (COPD) can be classified into groups
A/C or B/D based on symptom intensity. Different threshold values for symptom questionnaires can
result in misclassification and, in turn, different treatment recommendations. The primary aim was to
find the best fitting cut-points for Global initiative for chronic Obstructive Lung Disease (GOLD) symptom
measures, with an modified Medical Research Council dyspnea grade of 2 or higher as point of reference. Methods: After a computerized search, data from 41 cohorts and whose authors agreed to provide data
were pooled. COPD studies were eligible for analyses if they included, at least age, sex, postbronchodilator
spirometry, modified Medical Research Council, and COPD Assessment Test (CAT) total
scores.
Main outcomes: Receiver operating characteristic curves and the Youden index were used to determine
the best calibration threshold for CAT, COPD Clinical Questionnaire, and St. Georges Respiratory Questionnaire
total scores. Following, GOLD A/B/C/D frequencies were calculated based on current cut-points
and the newly derived cut-points.
Findings: A total of 18,577 patients with COPD [72.0% male; mean age: 66.3 years (standard deviation
9.6)] were analyzed. Most patients had a moderate or severe degree of airflow limitation (GOLD spirometric
grade 1, 10.9%; grade 2, 46.6%; grade 3, 32.4%; and grade 4, 10.3%). The best calibration threshold
for CAT total score was 18 points, for COPD Clinical Questionnaire total score 1.9 points, and for St.
Georges Respiratory Questionnaire total score 46.0 points.
Conclusions: The application of these new cut-points would reclassify about one-third of the patients
with COPD and, thus, would impact on individual disease management. Further validation in prospective
studies of these new values are needed.